Pecunity Launches Globally, Bridging Compliance and Innovation in Decentralized Finance

FREIBURG, Germany, Oct. 25, 2025 (GLOBE NEWSWIRE) — Pecunity, a next-generation decentralized finance (DeFi) platform, officially announces its launch, inviting crypto investors to earn additional APY on their digital assets through fully automated and transparent yield strategies. Built under the registered German software company 3Blocks UG, Pecunity delivers a compliant, audited, and user-friendly approach to […]

Pecunity Launches Globally, Bridging Compliance and Innovation in Decentralized Finance

Pecunity Launches Globally, Bridging Compliance and Innovation in Decentralized Finance GlobeNewswire October 25, 2025 FREIBURG, Germany, Oct. 25, 2025 (GLOBE NEWSWIRE) — Pecunity, a next-generation decentralized finance (DeFi) platform, officially announces its launch, inviting crypto investors to earn additional APY on their digital assets through fully automated and transparent yield strategies. Built under the registered

New Crypto Mutuum Finance (MUTM) Nears V1 Launch After Raising Over $17.8M

New Crypto Mutuum Finance (MUTM) Nears V1 Launch After Raising Over $17.8M GlobeNewswire October 25, 2025 Dubai, UAE, Oct. 25, 2025 (GLOBE NEWSWIRE) — In a market where many blockchain projects promise innovation but struggle with execution, Mutuum Finance (MUTM) is quickly emerging as one of the top crypto demonstrating steady, measurable progress. The Ethereum-based

I-Berhad Ushers in a New Era with First AI Robot with PBT Soaring 74% to RM26.8 Million in Q3FY2025

KUALA LUMPUR, MY / ACCESS Newswire / October 25, 2025 / I-Berhad ("I-Berhad" or the "Group"), the master developer of i-City – Malaysia’s No.1 Digital City, today announced its financial results for the third quarter ended 30 September 2025 ("Q3FY2025"), posting its highest-ever quarterly profit before tax ("PBT") of RM26.8 million. The record earnings underscore

Global Child “Travel & Purpose” & Picolinis Animal Rescue Siblings Unite to Protect Miami’s Precious Pets

Picolinis Animal Rescue is on a heartfelt mission to change lives – one paw at a time. Dedicated to rescuing, rehabilitating, and rehoming dogs of all ages, the organization places a special emphasis on senior and special-needs dogs who are too often overlooked. https://mma.prnewswire.com/media/2805085/Pico_001.jpg “Every dog deserves love, comfort, and a family to call their

CGTN: Restoring the History of Taiwan

Men forget, and history overlooks. But history is not, and must not become, a blank page to be written on at will, as there are courageous individuals like writerLan Bozhou, who deeply loves Taiwan, yet also carries a profound understanding of the suffering endured by the Chinese nation. The writer has devoted half his life

Renowned Indian Entrepreneur Deepinder Goyal Launches ‘Continue Research’ with a $25 Million Personal Fund to Reimagine Human Longevity

Deepinder Goyal, one of India's most respected self-made entrepreneurs, known for his contributions to entrepreneurship, innovation, mentorship, and ecosystem building, has announced the launch of Continue Research, supported by a $25 million personal fund dedicated to advancing global longevity science. https://mma.prnewswire.com/media/2805169/Continue_Research_Post.jpg Continue Researchwas founded two years ago as an independent scientific initiative exploring upstream biological

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Results showed consistently higher objective response rates (ORR) and longer progression-free survival (PFS) across

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch VenusMedtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium GlobeNewswire October 25, 2025 Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from

Scroll to Top